These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21088829)

  • 1. Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy.
    Corrao G; Romio SA; Zambon A; Merlino L; Bosi E; Scavini M
    Eur J Clin Pharmacol; 2011 Mar; 67(3):289-99. PubMed ID: 21088829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke.
    Floyd JS; Wiggins KL; Sitlani CM; Flory JH; Dublin S; Smith NL; Heckbert SR; Psaty BM
    Diabetes Obes Metab; 2015 Dec; 17(12):1194-7. PubMed ID: 26179389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study.
    Donnan PT; MacDonald TM; Morris AD
    Diabet Med; 2002 Apr; 19(4):279-84. PubMed ID: 11942998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study.
    Chang YC; Chuang LM; Lin JW; Chen ST; Lai MS; Chang CH
    Diabet Med; 2015 Nov; 32(11):1460-9. PubMed ID: 25970814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of initial oral antidiabetic treatment in patients with type 2 diabetes mellitus.
    Jermendy G; Wittmann I; Nagy L; Kiss Z; Rokszin G; Abonyi-Tóth Z; Katona L; Paragh G; Karádi I; Merkely B
    Med Sci Monit; 2012 Feb; 18(2):CR72-77. PubMed ID: 22293880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.
    Hippisley-Cox J; Coupland C
    BMJ; 2016 Jul; 354():i3477. PubMed ID: 27413012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to oral hypoglycaemic agents prior to insulin therapy in Type 2 diabetes.
    Evans JM; Donnan PT; Morris AD
    Diabet Med; 2002 Aug; 19(8):685-8. PubMed ID: 12147151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term comparative safety analysis of the risks associated with adding or switching to a sulfonylurea as second-line Type 2 diabetes mellitus treatment in a US veteran population.
    Powell WR; Christiansen CL; Miller DR
    Diabet Med; 2019 Nov; 36(11):1384-1390. PubMed ID: 30343492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular outcomes of type 2 diabetic patients treated with DPP‑4 inhibitors versus sulphonylureas as add-on to metformin in clinical practice.
    Bazo-Alvarez JC; Pal K; Pham TM; Nazareth I; Petersen I; Sharma M
    Sci Rep; 2021 Dec; 11(1):23826. PubMed ID: 34903733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.
    Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S
    Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.
    Rascati K; Richards K; Lopez D; Cheng LI; Wilson J
    Diabetes Obes Metab; 2013 Oct; 15(10):901-5. PubMed ID: 23531154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary care.
    Hippisley-Cox J; Coupland C
    BMJ; 2016 Mar; 352():i1450. PubMed ID: 27029547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
    Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
    Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guideline-conformity of initiation with oral hypoglycemic treatment for patients with newly therapy-dependent type 2 diabetes mellitus in Austria.
    Winkelmayer WC; Stedman MR; Pogantsch M; Wieninger P; Bucsics A; Asslaber M; Bauer R; Burkhardt T; Schautzer A; Brookhart MA;
    Pharmacoepidemiol Drug Saf; 2011 Jan; 20(1):57-65. PubMed ID: 21182153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study.
    Sullivan D; Forder P; Simes J; Whiting M; Kritharides L; Merrifield A; Donoghoe M; Colman PG; Graham N; Haapamäki H; Keech A;
    Diabetes Res Clin Pract; 2011 Nov; 94(2):284-90. PubMed ID: 21862166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure.
    Bowker SL; Yasui Y; Veugelers P; Johnson JA
    Diabetologia; 2010 Aug; 53(8):1631-7. PubMed ID: 20407744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
    Berkowitz SA; Krumme AA; Avorn J; Brennan T; Matlin OS; Spettell CM; Pezalla EJ; Brill G; Shrank WH; Choudhry NK
    JAMA Intern Med; 2014 Dec; 174(12):1955-62. PubMed ID: 25347323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of diabetes-associated secondary healthcare utilization between alternative oral antihyperglycaemic dual therapy combinations with metformin in patients with type 2 diabetes: an observational cohort study.
    Strongman H; D'Oca K; Langerman H; Das R
    Diabetes Obes Metab; 2015 Jun; 17(6):573-580. PubMed ID: 25735201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.